Maya E. Takashima

This study shows that optimized spatially heterogeneous radiopharmaceutical therapy enhances immune checkpoint blockade response in poorly immunogenic tumors by promoting T cell activation and infiltration.

This study shows that heterogeneous radiation dose in tumors enhances anti-tumor immunity and correlates with better clinical outcomes in prostate cancer patients.

This study compares the immune effects of alpha- and beta-particle emitting radiopharmaceuticals combined with immune checkpoint inhibitors in murine tumor models, finding distinct mechanisms of action based on radiation type.